Lu-177 PSMA therapy: published outcomes and cost
How published Lu-177 PSMA trial outcomes differ from an individual prognosis, and where to request an itemised cost estimate.
Editorial update: 3 November 2026. The study references below describe published research, not TPPL-specific outcome rates.
What does a treatment response mean?
Response can refer to changes on imaging, PSA, symptoms or the time before disease progression. These measures are not interchangeable. A published study result is not a guarantee for an individual patient.
What VISION studied
VISION was a randomised study in selected patients with PSMA-positive metastatic castration-resistant prostate cancer after specified previous treatment. Adding Lu-177 PSMA-617 to the trial's standard-care approach improved the measured progression and survival outcomes. Its eligibility criteria and comparator matter when discussing whether the findings apply to a different patient.
What affects an individual discussion?
The team reviews the current PSMA PET-CT, previous therapies, symptoms, marrow and organ function, and the treating oncologist's plan. Published averages do not predict how long a particular person will live.
Cost
Request an itemised per-cycle and course estimate for the proposed product and plan. Check imaging, laboratory work, admission and medicines separately. Lu-177 PSMA therapy cost in India is the dedicated cost page.
Questions to discuss with the treating team
Is a trial response rate my personal chance of benefit?
No. The study population, endpoint and previous treatments must be compared with the individual clinical situation.
Does a lower PSA alone establish the full response?
The treating team assesses PSA alongside imaging, symptoms and safety results.